DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.
DiogenX has raised €32M across 2 funding rounds from 6 investors, most recently a Series A round in May 2023. Based in Marseille, France; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2023-05-10 | Series A | €28M | AdBio partners,Boehringer Ingelheim Venture Fund,Eli lilly and company,JDRF T1D Fund,Omnes Capital,Roche Venture Fund | View deal → |
| 2020-06-16 | Seed | €4.5M | — | View deal → |
